Agenus Inc.

As of June 30, 2026, Agenus Inc. carries a market capitalization of 114.21M, placing it among publicly traded companies globally. Its enterprise value stands at 127.51M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Agenus Inc.'s next confirmed earnings release is scheduled for November 10, 2026.

As of June 30, 2026, Agenus Inc. has 42.62M shares outstanding.

As of June 30, 2026, Agenus Inc. trades at a trailing price-to-earnings ratio of 1.22. The price-to-sales ratio is 0.85, and the price-to-book ratio stands at -0.66.

As of June 30, 2026, Agenus Inc. trades at an EV/EBITDA multiple of 3.56 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.10 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 4.02 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 127.51M versus a market cap of 114.21M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Agenus Inc. maintains a current ratio of 0.34, meaning it holds 0.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -19.78, indicating conservative leverage, while an interest coverage ratio of 0.69 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) stands at 51.42, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is negative at -73.58, pointing to unprofitable operations over the period. The company generates approximately 831,099.70 in revenue per employee across its workforce of 139.75, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, Agenus Inc.'s stock has gained approximately 63.35% over the past 52 weeks. The 50-day moving average sits at 6.74, while the 200-day moving average is 4.22.

Over the twelve months ended June 30, 2026, Agenus Inc. generated 116.15M in revenue and converted that into 80.54M in net income, yielding earnings per share of 2.18. EBITDA reached 35.82M, while operating income came in at 31.41M.

As of June 30, 2026, Agenus Inc. holds 16.40M in cash and equivalents against 35.63M in total debt, resulting in a net debt position of 9.92M. Total book value stands at -174.25M, with working capital of -133.93M providing operational flexibility.

Agenus Inc. produced -86.22M in operating cash flow over the twelve months ended June 30, 2026. After subtracting - - in capital expenditures, free cash flow totaled -86.22M - equivalent to -2.35 per share.

Over the twelve months ended June 30, 2026, Agenus Inc. posted a gross margin of 56.04, reflecting its pricing power and cost economics. The operating margin of 27.04 and net profit margin of 69.34 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. The dividend payout ratio of -0.24 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -87.07: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -27.40, meaning Agenus Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Agenus Inc.'s most recent stock split took place on April 12, 2024 with a 20:1 split ratio.

As of June 30, 2026, Agenus Inc. has an Altman Z-Score of -19.93, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.